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Abstract
Introduction: The F3 peptide (KDEPQRRSARLSAKPAPPKPEPKPKKAPAKK), a fragment of the human high mobility
group protein 2, binds nucleolin. Nucleolin is expressed in the nuclei of normal cells but is also expressed on the
membrane of some cancer cells. The goal was to investigate the use of
111In-labeled F3 peptide for Auger
electron-targeted radiotherapy.
Methods: F3 was labeled with fluorescein isothiocyanate (FITC) for confocal microscopy and conjugated to p-SCN-
benzyl-diethylenetriaminepentaacetic acid (BnDTPA) for labeling with
111In to form
111In-BnDTPA-F3. MDA-MB-231-
H2N (231-H2N) human breast cancer cells were exposed to
111In-BnDTPA-F3 and used in cell fractionation, gH2AX
immunostaining (a marker of DNA double-strand breaks), and clonogenic assays. In vivo, biodistribution studies of
111In-BnDTPA-F3 were performed in 231-H2N xenograft-bearing mice. In tumor growth delay studies,
111In-BnDTPA-
F3 (3 μg, 6 MBq/μg) was administered intravenously to 231-H2N xenograft-bearing mice once weekly for 3 weeks.
Results: Membrane-binding of FITC-F3 was observed in 231-H2N cells, and there was co-localization of FITC-F3
with nucleolin in the nuclei. After exposure of 231-H2N cells to
111In-BnDTPA-F3 for 2 h, 1.7% of
111In added to the
medium was membrane-bound. Of the bound
111In, 15% was internalized, and of this, 37% was localized in the
nucleus. Exposure of 231-H2N cells to
111In-BnDTPA-F3 (1 μM, 6 MBq/μg) resulted in a dose-dependent increase in
gH2AX foci and in a significant reduction of clonogenic survival compared to untreated cells or cells exposed to
unlabeled BnDTPA-F3 (46 ± 4.1%, 100 ± 1.8%, and 132 ± 7.7%, respectively). In vivo, tumor uptake of
111In-BnDTPA-
F3 (3 μg, 6 MBq/μg) at 3-h post-injection was 1% of the injected dose per gram (%ID/g), and muscle uptake was
0.5%ID/g. In tumor growth delay studies, tumor growth rate was reduced 19-fold compared to untreated or
unlabeled BnDTPA-F3-treated mice (p = 0.023).
Conclusion:
111In-BnDTPA-F3 is internalized into 231-H2N cells and translocates to the nucleus.
111In-BnDTPA-F3
has a potent cytotoxic effect in vitro and an anti-tumor effect in mice bearing 231-H2N xenografts despite modest
total tumor accumulation.
Keywords: F3 peptide, Auger electron, nucleolin, nucleolus,
111In.
Introduction
Targeted radiotherapy uses alpha-, beta-, or Auger elec-
tron emissions from radionuclides to specifically irradi-
ate cancer cells and cause tumor growth arrest. Well-
established examples include the FDA-approved beta-
particle-emitting drugs Bexxar (
131I-tositumomab) and
Zevalin (
90Y-ibritumomab tiuxetan) for the treatment of
CD20-positive non-Hodgkin’s lymphoma [1]. Auger
electron radiation therapy differs from alpha and beta
particle therapy because of the extremely short path-
length of the low-energy electrons that are emitted
[2-7]. Cellular internalization and subsequent nuclear
localization are deemed necessary for Auger electron
radiation to be effective for cancer therapy [8]. The
tumor-homing peptide F3, a 31-mer peptide
(KDEPQRRSARLSAKPAPPKPEPKPKKAPAKK), derived
from human high mobility group protein 2 (HMGN2)
has been shown to bind specifically to nucleolin
expressed on the membrane of cancer cells, neovascula-
ture, and endothelium. After binding, F3 internalizes
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[9,10]. Zhang et al. targeted MCF7 cells using F3-conju-
gated dextran-coated iron oxide nanoparticles [11]. F3
peptide has also been used for the delivery of photody-
namic therapy agents, iron oxide nanoparticles, siRNA,
and oligonucleotides to various tumor cell lines and
tumor xenografts [12-15]. Winer et al. have recently
demonstrated targeting of F3-conjugated cisplatin-
hydrogel nanoparticles to the vessels of various tumor
xenografts [16]. Bhojani et al. and Van Dort et al. have
recently reported on the use of radioiodine-labeled F3
peptide for single-photon emission computed tomogra-
phy (SPECT) imaging [17,18]. A F3-peptide dimer
labeled with the alpha-emitter
213Bi (
213Bi-(F3)2)f o r
molecular radiotherapy of membranar-nucleolin-expres-
sing MDA-MB-435 cells was shown to be effective in
vitro and in xenografts in mice [19]. When F3 was
labeled with
67Ga, it accumulated in MDA-MB-435
tumor xenografts in vivo, as shown by PET imaging
[19].
In the current report, an Auger electron-emitting,
111In-labeled (t1/2 = 2.9 days), benzyl-diethylenetriamine-
pentaacetic acid (BnDTPA) conjugated monovalent var-
iant of the F3 peptide is described. Auger electrons are
low-energy and are emitted by radionuclides that decay
by electron capture. Their very short pathlength
(approximately 1 nm to 1 μm), but with high linear
energy transfer-like characteristics, means that they can
cause irreparable and cell-lethal clustered DNA damage
when they are emitted inside the nucleus, in close proxi-
mity to DNA. Here, we show that
111In-BnDTPA-F3
internalizes into the cells and translocates to the nuclei
a n dn u c l e o l i ,a n dt h a tt h eA u g e re l e c t r o ne m i s s i o n
causes DNA double-strand breaks (DNA dsb) and cyto-
toxicity. The clonogenic survival of cells exposed to
111In-BnDTPA-F3, its biodistribution in xenograft-bear-
ing mice, and ability to arrest tumor xenograft growth
are reported.
Materials and methods
Cell lines
MDA-MB-231 cells, stably transfected with the HER2
gene yielding MDA-MB-231-H2N cells (referred to as
231-H2N), were a gift from Dr. R. Kerbel (Sunnybrook
Health Sciences Centre, Toronto, Ontario, Canada) [20].
Cells were cultured at 37°C in 5% CO2 using Dulbecco’s
modified eagle medium (DMEM) cell culture medium
(Sigma-Aldrich, Dorset, UK) supplemented with a 10%
fetal calf serum (Invitrogen, Paisley, UK) and penicillin/
streptomycin, 100 units/mL (Invitrogen, Paisley, UK).
Synthesis of
111In-BnDTPA-F3
F3 peptide (KDEPQRRSARLSAKPAPPKPEPKPKKA-
PAKK, MW = 3432 g/mol) was obtained from
Cambridge peptides (Cambridge, UK). Size and purity
were confirmed by reverse phase HPLC and mass spec-
troscopy. F3 peptide (100 μg dissolved in 100 μL0 . 1M
sodium bicarbonate, pH 8.4) was reacted with a fivefold
molar excess of p-SCN-BnDTPA (Macrocyclics, Dallas,
TX, USA), dissolved in dry DMSO (Sigma, Gillingham,
Dorset, UK) at room temperature for 1 h, resulting in
BnDTPA-F3. Unconjugated BnDTPA was removed by
centrifugation using a YM-3 microfilter (Millipore, Bill-
erica, MA, USA). BnDTPA-F3 peptide was buffer-
exchanged in 0.1 M sodium citrate pH 5.0. The DTPA
conjugation rate was determined as previously described
by Hnatowich et al. [21] and was found to be 0.85:1 to
0.95:1 DTPA/F3.
111In chloride (0.1 to 9 MBq/μg, 0.34
to 30.9 MBq/nmol) (Perkin Elmer, Waltham, MA, USA)
was added, resulting in
111In-BnDTPA-F3. After incuba-
tion at room temperature for 1 h, radiolabeling yield
was measured using instant thin layer chromatography
(Amersham Health, Amersham, UK) in 0.1 M sodium
citrate pH 5.0 and was always ≥ 95%.
Confocal microscopy
The 231-H2N cells were seeded on coverslips and
allowed to adhere overnight. Cells were exposed to 10-
nM fluorescein isothiocyanate (FITC)-conjugated F3
peptide (Phoenix Pharmaceuticals, Karlsruhe, Germany)
for 2 h at 37°C. Cells were washed with phosphate buf-
fered saline (PBS), fixed for 10 min at room temperature
with 4% paraformaldehyde (Sigma-Aldrich Corporation,
St. Louis, MO, USA), permeabilized at room tempera-
ture using 1% Triton X-100 in PBS (Sigma), and blocked
(1 h at 37°C, 2% BSA in PBS). Cells were immunos-
tained for nucleolin using mouse anti-nucleolin IgG as
primary antibody for 1 h at 37°C (1:2,000, ab13541;
Abcam, Cambridge, UK), incubated with Alexa Fluor
555 goat anti-mouse IgG (1:250; Invitrogen, Paisley,
UK), and mounted using Vectashield mounting medium
with DAPI (Vector labs, Peterborough, UK). Confocal
microscopy images were acquired using a Zeiss 530
microscope (Zeiss, Welwyn Garden City, UK).
Internalization and nuclear localization of
111In-BnDTPA-
F3
Internalization and retention of
111In-BnDTPA-F3 were
determined as previously described by Cornelissen et al.
[22]. Briefly, 2 × 10
5 cells were seeded per well in 24-
well plates, and
111In-BnDTPA-F3 was then added (1
μM in 200 μLD M E M ,6M B q / μg). For internalization
assays, the supernatant was removed at selected time
points, and cells were washed using 0.1 M glycine HCl
pH 2.5 to remove cell-surface bound
111In-BnDTPA-F3.
Cells were then lyzed using 0.1 M NaOH. Radioactivity
in fractions containing supernatant, cell-surface bound,
and internalized radiopeptide was counted using an
Cornelissen et al. EJNMMI Research 2012, 2:9
http://www.ejnmmires.com/content/2/1/9
Page 2 of 11automated gammacounter system (Wizard, PerkinElmer,
Waltham, MA, USA). In some cases, a 100-fold molar
excess of cold, unlabeled F3 or anti-nucleolin antibody
(ZN004; MBL International, Woburn, MA, USA) was
added. ZN004 has been shown to block the uptake of
fluorescently labeled F3 peptide by inhibiting internali-
zation of nucleolin [13]. For nuclear localization assays,
aliquots of 10
6 cells in 500 μL of growth medium were
exposed to
111In-BnDTPA-F3 (1 μM in 200 μLD M E M ,
6 MBq/μg). At selected time points, the supernatant was
removed, and cells were washed with 0.1 M glycine HCl
pH 2.5 to remove cell-surface bound F3. The cell mem-
brane was lysed (25 mM KCl, 5 mM MgCl2,1 0m M
Tris-HCl, and 0.5% NP-40; 6 min on ice) [22,23]. The
cytoplasmic fraction was separated by centrifugation.
Nuclei were washed with PBS and lysed using 0.1 M
NaOH. Radioactivity in the fractions containing super-
natant, cell-surface bound, cytoplasmic, and nucleus-
associated
111In was counted using an automated gam-
macounter system. We previously demonstrated by
Western blot for calpain, an abundant cytoplasmic pro-
tein and p84, a nuclear matrix protein (unpublished
results), that this method provides a highly pure nuclear
and cytoplasm/membrane fraction.
Microdosimetry
Using the data obtained from nuclear localization assays,
time-activity curves were generated for each of the com-
partments of the cell: membrane, cytoplasm, and
nucleus. Using S values tabulated by Goddu et al., the
radiation dose delivered to the nucleus of 231-H2N cells
was calculated [24].
gH2AX assay
The 231-H2N cells (2 × 10
5) were seeded in 96-well
plates and left to adhere overnight. Fresh growth med-
ium (2 mL) containing various amounts (0 to 5 μM) of
cold, unlabeled BnDTPA-F3 or
111In-BnDTPA-F3 (6
MBq/μg) was added. X-ray irradiated cells (4 Gy) were
used as a positive control. After incubation at 37°C for 2
or 24 h, cells were washed, fixed, permeabilized, and
blocked. Samples were stained for gH2AX as described
previously by Nakamura et al. [25]. Fluorescence images
were acquired using an IN Cell analyzer (GE Healthcare,
P i t t s b u r g h ,P A ,U S A ) .T h en u m b e ro fgH2AX foci per
cell was counted automatically using the IN Cell analysis
software. In a separate experiment, cells were exposed to
BnDTPA-F3 (2 μM) at increasing specific activities (0 to
6M B q / μg or 0 to 20.6 MBq/nmol) for 2 h, and the
number of gH2AX foci was determined as above.
Clonogenic survival
Aliquots of 231-H2N cells (2 × 10
5)w e r ee x p o s e dt o
various concentrations (range, 0 to 1 μM) of cold,
unlabeled BnDTPA-F3 or
111In-BnDTPA-F3 (6 MBq/
μg). After incubation at 37°C for 24 h, 2 × 10
3 cells
were seeded per well in a 6-well plate, and 2 mL of
fresh growth medium was added. After 7 to 14 days, cell
colonies were stained with methylene blue (2% methy-
lene blue in water/methanol 1:1) and counted. Combi-
nation indices (CI) of
111In with BnDTPA-F3 were
determined as described by Edelman et al. [26]. A CI <
0.9 indicates superadditivity.
In vivo biodistribution and SPECT imaging
All animal procedures were carried out in accordance
with the United Kingdom Animals (Scientific Proce-
dures) Act 1986 and with the local ethical committee
approval. The 231-H2N xenografts were established in
female balb/c nu/nu mice (Harlan, UK) by subcutaneous
injection in the right flank of 5 × 10
6 cells in DMEM/
matrigel 1:1 (Matrigel; BD Biosciences, Oxford, UK).
When xenografts reached a volume of approximately
500 μL,
111In-BnDTPA-F3 (3 μg, 6 MBq/μg) was admi-
nistered to the mice intravenously (i.v.) (n = 3). Preli-
minary kinetic planar gamma imaging showed that a
plateau for tumor uptake was reached after 3 h (data
not shown). Therefore, at 3 h after injection, static
SPECT images were acquired using a nanoSPECT/CT
system (Bioscan, Washington DC, USA). After SPECT
imaging, animals were euthanized, and blood, selected
normal tissues, and tumor were removed. Tissues were
washed in PBS and blot dried, weighed, and counted for
radioactivity. The amount of
111In in blood and tissues
was expressed as a percentage of the injected dose per
gram (%ID/g) of blood/tissue.
Tumor growth inhibition
The 231-H2N xenografts were established in female
balb/c nu/nu mice as described above. When xenografts
reached a volume of approximately 100 μL, PBS (con-
trol), unlabeled F3 peptide or
111In-BnDTPA-F3 (3 μg, 6
MBq/μg) was administered i.v. to the mice (seven per
group) on days 1, 8, and 15. Tumor size was measured
by a caliper twice weekly. Tumor volume was calculated
as V = a
2 × b, where a and b are the short and long
axes, respectively. Animals were euthanized when the
tumor diameter reached 12.5 mm. Tumor growth rate
(K) was estimated by fitting the volume data to V = V0
× e
k×t , where V is the tumor volume in mm
3, V0 is the
volume at the start of the experiment, t is the time after
treatment in days, and K is the growth rate expressed in
mm
3/day.
Statistical analysis
All statistical analyses were performed using GraphPad
Prism (GraphPad Software, Inc., La Jolla, CA, USA).
Data are reported as mean ± standard deviation of at
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gH2AX foci analysis, where the results are expressed as
mean ± standard error of at least 200 cells per condi-
tion. One-way or two-way ANOVA was used for multi-
ple comparisons. Tukey post-tests were used after one-
way ANOVA. The F-test was used to compare fitted
curves. Kaplan-Meier curves were generated for survival
analysis. Log-rank tests were performed to compare
Kaplan-Meier survival curves.
Results
Intracellular distribution of FITC-F3 and
111In-BnDTPA-F3
Confocal microscopy showed membrane-bound and
internalized fluorescence in 231-H2N cells after expo-
sure to FITC-F3 for 2 h. FITC-F3 was observed to be
present in nuclei. Based on density measurements,
nuclear localization of FITC-F3 was approximately
33.6% of the total amount internalized. There, it co-
localized with nucleolin in nucleoli. Representative con-
focal images of the intracellular distribution of FITC-F3
and nucleolin in 231-H2N cells are shown in Figure 1.
Cell fractionation experiments were performed to evalu-
ate the extent of cellular and nuclear uptake of
111In-
BnDTPA-F3 in 231-H2N cells. After exposure of 231-
H2N cells to 1-μM
111In-BnDTPA-F3 for 2 h, 0.51 ±
0.03% of the total added
111In was internalized (Figure
2B). When an excess of cold, unlabeled F3 or anti-
nucleolin antibody was added, internalization of
111In-
BnDTPA-F3 was decreased significantly (p <0 . 0 0 1 ) .O f
the internalized fraction of
111In-BnDTPA-F3, 37%
translocated to the nuclei, similar to the 33.6% found
for FITC-F3. Nuclear localization plateaued after 30 min
at values of 0.15 ± 0.05% (Figure 2C). Using these data,
the radiation absorbed dose to 231-H2N cells was calcu-
lated using S value tables [24]. It was estimated that the
exposure of 231-H2N cells to 1-μM
111In-BnDTPA-F3
(6 MBq/μg) resulted in a radiation absorbed dose 10.8
Gy over 2 h. The contributions from the membrane,
cytoplasm, and nucleus were 2.3, 1.3, and 7.1 Gy,
respectively.
gH2AX assay
The number of gH2AX foci, a measure for the number
of DNA dsb, increased slightly after a 2-h exposure of
231-H2N cells to cold, unlabeled BnDPTA-F3. After
incubation with BnDPTA-F3 for 24 h, the number of
gH2AX foci in 231-H2N cells did not change signifi-
cantly. However, the number of gH2AX foci per cell
increased in a dose-dependent manner in 231-H2N cells
that were exposed to
111In-BnDTPA-F3, following incu-
bation for 2 or 24 h (F-test, p < 0.001) (Figure 3A, B).
Irradiated cells (4 Gy), used as a positive control, had
significantly more foci/cell compared with the untreated
control cells (p < 0.0001). The number of gH2AX foci 2
h after irradiation (4 Gy) was not significantly different
from that after
111In-BnDTPA-F3 (6 MBq/μg) at con-
centrations higher than 0.2 μM( p > 0.05). Furthermore,
gH2AX foci induction was linearly dependent of the
specific activity used (Spearman, R = 0.99; p = 0.0028).
Clonogenic survival assay
Clonogenic survival of 231-H2N cells was reduced sig-
nificantly by increasing concentrations of
111In-
BnDTPA-F3 (Figure 4A). The surviving fraction was
reduced to 10% after exposure to
111In-BnDTPA-F3 (3
μM, 6 MBq/μg) for 24 h (p < 0.001). In contrast, expo-
sure to cold, unlabeled BnDTPA-F3 did not significantly
reduce clonogenic survival. To evaluate the effect of
increased specific activity, clonogenic survival of 231-
H2N cells was also evaluated after exposure to
111In-
BnDTPA-F3 (up to 2 μM) of increasing specific activity
ranging from 0 to 9 MBq/μg (Figure 4B). The increasing
specific activity of a 2-μM amount of
111In-BnDTPA-F3
resulted in a 4.6-fold decrease in clonogenic survival
from 74.5 ± 5.8% to 16 ± 0.5% compared with the unex-
p o s e dc e l l s .A ne q u i v a l e n ta m o u n to f
111In chloride
Nucleolin  FITC-F3  DAPI Merge 
Figure 1 FITC-F3 confocal microscopy. The 231-H2N cells were exposed to fluorescein isothiocyanate (FITC)-F3 (10 nM) for 2 h. FITC-F3 is
shown in green and nucleolin in red. Nuclei were stained with DAPI (blue). Images of a representative cell are shown.
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Figure 2 Cellular and nuclear uptake of
111In-BnDTPA-F3. The 231-H2N cells were exposed to
111In-benzyl-diethylenetriaminepentaacetic
acid (BnDTPA)-F3 alone or in combination with a 100-fold molar excess of cold, unlabeled BnDTPA-F3 or anti-nucleolin antibody for various
times. (A) Membranar fraction, (B) cellular internalization, and (C) nuclear localization of
111In were determined. Results are expressed as mean ±
SD of three independent repeats.
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Figure 3 Induction of DNA double-strand breaks by
111In-BnDTPA-F3. The 231-H2N cells were X-irradiated (IR, 4 Gy) or exposed to
111In-
BnDTPA-F3 (0 to 5 μM, 20.6 MBq/nmol), an equivalent amount of
111In chloride, or cold, unlabeled BnDTPA-F3 for (A)2ho r( B) 24 h. Cells were
fixed and stained for gH2AX. The number of gH2AX foci per cell was determined. Results are expressed as mean ± SEM, n = 200 per condition.
(C) The 231-H2N cells were exposed to
111In-BnDTPA-F3 (2 μM) with varying specific activities (0 to 6 MBq/μg) for 2 h and treated as above.
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4% only. Combination indices were 1.08 and 1.49 at 3
MBq/μga t1a n d2μM, respectively, but ranged from
0.66 to 0.14 for 6 and 9 MBq/μg at 1 and 2 μM, indicat-
ing superadditivity between
111In and F3.
In vivo biodistribution of
111In-BnDTPA-F3
A representative SPECT maximum intensity projection,
3 h after intravenous injection of 3 μgo f
111In-
B n D T P A - F 3( 6M B q / μg), is shown in Figure 5A. The
biodistribution of
111In-BnDTPA-F3 was determined 3 h
after i.v. injection of 3 μg( 6M B q / μg). The results are
summarized in Figure 5B.
111In-BnDTPA-F3 was mainly
t a k e nu pi nt h ek i d n e y s( 7 . 0±1 . 6 % I D / g ) .
111In-
BnDTPA-F3 concentration in the blood was relatively
high for a peptide of this size (3.2 ± 1.6%ID/g). Tumor
uptake was modest (0.80 ± 0.28%ID/g).
Tumor growth inhibition
The 231-H2N xenograft tumors in mice that received
t h r e ew e e k l yd o s e so f
111In-BnDTPA-F3 (3 μg, 6 MBq/
μg) grew significantly slower compared with those in
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Figure 4 Clonogenic survival of cells after exposure to
111In-BNDTPA-F3. (A) Clonogenic survival of 231-H2N cells, exposed for 24 h to
increasing concentrations (0 to 3 μM) of
111In-BnDTPA-F3 (20.6 MBq/nmol), or cold, unlabeled BnDTPA-F3. (B) Clonogenic survival of 231-H2N
cells, exposed for 24 h to increasing concentrations (0 to 2 μM) of
111In-BnDTPA-F3, at increasing specific activities (0 to 30.9 MBq/nmol), or
equivalent amounts of
111In chloride. Results are expressed as mean ± SD of three independent repeats.
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control (growth rate = 0.0043 ± 0.0061, 0.080 ± 0.019,
and 0.082 ± 0.013 mm
3/day, respectively; p = 0.0031)
(Figure 6A, B). Kaplan-Meier curves showed a signifi-
c a n td i f f e r e n c ei nt i m ef o rt h et u m o rt og r o wt w i c ei t s
original volume (p = 0.0073) (Figure 6C) as well as sur-
vival time (p = 0.0174) (Figure 6D).
Discussion
Auger electron radiation therapy has been investigated
extensively for the eradication of cancer, in vitro and in
vivo in pre-clinical models [8]. In this report, an Auger
electron-emitting,
111In-labeled radiopharmaceutical,
based on the HMGN2-protein-derived F3 peptide is pre-
sented. It was shown that FITC-F3 binds to 231-H2N
cells, internalizes, and translocates to the nucleus (Fig-
ure 1), confirming previously reported data [11,16,18].
This not only proves F3 internalization in the model cell
line used here, 231-H2N, but furthermore suggests that
when radiolabeled the same peptide might also be taken
up into these cells and their nuclei.
111In-BnDTPA-F3
also internalizes into these cells and is taken up into the
nucleus (Figure 2) in a nucleolin-dependent fashion, as
indicated in experiments in which cold, unlabeled F3
peptide and anti-nucleolin antibodies were used to block
uptake. As suggested by Henke et al., blockage of inter-
nalization by the anti-nucleolin antibody, ZN004, is
most likely not due to steric hindrance but to antibody-
dependent blockage of nucleolin internalization [13].
Even though only 0.15% of the total added
111In accu-
mulates in the nuclei of 231-H2N cells, the nuclear
uptake of
111In-BnDTPA-F3 was sufficient to result in
the formation of DNA dsb. This dose-dependent DNA
damage formation occurs rapidly as already 2 h after
addition of
111In-BnDTPA-F3 gH2AX foci could be
o b s e r v e d .T h ei n d u c t i o no fD N Ad s bi nt u r nl e dt oa
dose-dependent decrease in clonogenic survival (Figure
4A). The effect of increasing specific activity shown in
Figure 4B further corroborates the finding that reduced
clonogenic survival is caused by the radiotoxicity of
111In. In vivo, after intravenous injection in mice bearing
a 231-H2N xenograft, overall tumor uptake of
111In-
BnDTPA-F3 is modest, but the growth of the tumor can
be slowed significantly by
111In-BnDTPA-F3, but not
unlabeled BnDTPA-F3.
Drecoll et al. reported extensive and rapid nuclear
localization of
213Bi-DTPA-(F3)2 in MDA-MB-435 cells
[19], while the results in this paper show that cellular
internalization of
111In-BnDTPA-F3, albeit in a different
cell line, was low and increased steadily up to 2 h.
Nuclear internalization of
111In-DTPA-F3 was 37% of
the total cellular uptake in 231-H2N cells, whereas
nucleus-associated
213Bi exceeded 75% of cell-bound
213Bi. Although these studies were performed in differ-
ent cells, this discrepancy in nuclear uptake might be
explained by the bi-valency of the
213Bi compound
(monomer vs. dimer).
Given the relatively longer pathlength of alpha parti-
cles (50 to 100 μm), there is no requirement for
213Bi-
DTPA-(F3)2 to internalize into the tumor cells; associa-
tion with the membrane of tumo rc e l l si ss u f f i c i e n t .I n
contrast, the Auger electrons emitted by
111In have a
blood
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Figure 5 In vivo biodistribution of
111In-BnDTPA-F3.( A) Representative SPECT image of the distribution of
111In-BnDTPA-F3 in 231-H2N
xenograft-bearing mice, 3-h post-intravenous injection. G, gall bladder; K, kidneys; S, spleen; B, bladder. (B) Biodistribution of
111In-BnDTPA-F3, 3-h
post-intravenous injection. Results are expressed as the average percentage of the injected dose per gram (%ID/g) of tissue ± SD of the three
mice.
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the first few nanometers [6]. Therefore, it is hypothe-
sized that nuclear localization is necessary for Auger
electron therapy to be effective. It was shown here that
111In-BnDTPA-F3 does not internalize into the cells in
large quantities but, nevertheless, results in a radiation
absorbed dose to tumor cell nu c l e io f1 0 . 8G y ,w h i c hi s
comparable to other Auger electron-emitting agents
[24]. This is further corroborated by the presence of
gH2AX foci in cells, shortly after exposure to
111In-
BnDTPA-F3, and by the linear correlation between spe-
cific activity and gH2AX foci induction. Taken together,
these results suggest that
111In-BnDTPA-F3 causes
nucleolin-specific,
111In-specific radiocytotoxicity in 231-
H2N cells.
The biodistribution of
111In-BnDTPA-F3 in a xeno-
graft-bearing mouse, 3 h after intravenous injection, was
comparable to that of
68Ga-DOTA-F3 as it also showed
high kidney uptake and low liver signal, indicating that
the excretion of this small labeled peptide occurs for the
most part through a renal clearance. However, tumor
uptake of
111In-BnDTPA-F3 was much lower (1.0%ID/g)
compared with that of
213Bi-(F3)2 (32%ID/g). This may
be attributed to the locoregional (intraperitoneal)
administration used for
213Bi-(F3)2 or to the bivalency of
the
213Bi-compound causing increased avidity. Another
possibility is that the relatively large size of
213Bi-(F3)2
could prolong its global retention. Interestingly, in a
recent report by Bhojani et al., the uptake of a
125I-
labeled F3 peptide in MDA-MB-435 xenografts was
much closer to that of
111In-BnDTPA-F3 than
213Bi-(F3)
2, being 1.05% ID/g at 30 min following i.v. injection
[17]. Most likely, the rapid renal clearance of
125I-F3
and
111In-BnDTPA-F3 following intravenous injection
limits the bioavailability of F3. Although no saturation
of
111In-BnDTPA-F3 cell association was observed in
vitro [see Figure 1 in Additional file 1], it is also possible
that saturation of the tumor cell membranar nucleolin
by F3 peptides is responsible for the modest tumor
uptake (3 and 19 μgo f
111In-BnDTPA-F3 and
125I-F3
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Figure 6 In vivo xenograft growth inhibition by
111In-BnDTPA-F3. Mice, bearing 231-H2N xenografts, were injected intravenously with PBS,
BnDTPA-F3, or
111In-BnDTPA-F3. Tumor size was measured twice weekly by a caliper. (A) Normalized tumor volume. (B) Growth rate (K)i nm m
3
per day. Results are expressed as average growth rates of tumors in seven mice ± SEM. **p = 0.0031. (C) Kaplan-Meier survival curves generated
using the time tumors reached twice the size at the beginning of the study (V =2V0). (D) Kaplan-Meier survival curves. Mice were killed when the
tumor reached its maximally allowed volume (V =Vmax).
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213Bi-(F3)2).
Although tumor uptake of
111In-BnDTPA-F3 was
modest, i.v. administration of
111In-BnDTPA-F3 signifi-
cantly inhibited the growth of 231-H2N xenograft
tumors. Given the extremely high dose deposition
around a decaying
111In nuclide (up to 5,000 Gy
absorbed in the 10-nm range), there is no necessity for
a high tumor uptake, as long as the intracellular traffick-
ing of
111In ensures its close proximity to densely
packed DNA, as in the nucleolus. Interestingly, it has
recently been highlighted in the literature that nucleolar
function is particularly sensitive to cellular stress includ-
ing that caused by UV and ionizing radiation [27,28]. In
particular, it has emerged that the nucleolus is directly
involved in p53 regulation so that nucleolar disruption
may be associated with changes in cell cycle and apop-
tosis [29]. It is, therefore, intriguing to speculate that
even modest accumulation of radioactivity in the
nucleoli, by causing disruption of stress-response co-
ordination, could have a disproportionately detrimental
effect on cell survival. It has been reported that intrave-
nously injected FITC-F3 localized in CD31 positive
tumor vessels [9,10,16,18]. Therefore, it is possible that
some of the anti-tumor effect of
111In-BnDTPA-F3
results from targeting of the tumor vasculature. Taken
together, these results suggest that
111In-BnDTPA-F3 is
capable of causing significant tumor growth inhibition.
Conclusion
111In-BnDTPA-F3 is an Auger electron-emitting radio-
pharmaceutical that internalizes in tumor cells where it
accumulates in the nucleus and, in particular, in the
nucleoli, causing decreased clonogenic survival in vitro
and tumor growth inhibition in vivo.
Additional material
Additional file 1: Internalization and nuclear localization of
111In-
BnDTPA-F3. The 231-H2N cells were seeded per well in 24-well plates,
and
111In-BnDTPA-F3 was then added (6 to 1,360 μg/mL in 200 μL
DMEM, 6 MBq/mg) for 2 h at 37°C. Cells were washed three times with
PBS, and cell-associated radioactivity was counted.
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